Last reviewed · How we verify
hepatic artery infusion chemotherapy
hepatic artery infusion chemotherapy is a Small molecule drug developed by RenJi Hospital. It is currently in Phase 1 development. Also known as: HAIC.
At a glance
| Generic name | hepatic artery infusion chemotherapy |
|---|---|
| Also known as | HAIC |
| Sponsor | RenJi Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus (PHASE2)
- HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
- Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial) (PHASE2)
- TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens (PHASE2)
- Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
- Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hepatic artery infusion chemotherapy CI brief — competitive landscape report
- hepatic artery infusion chemotherapy updates RSS · CI watch RSS
- RenJi Hospital portfolio CI
Frequently asked questions about hepatic artery infusion chemotherapy
What is hepatic artery infusion chemotherapy?
hepatic artery infusion chemotherapy is a Small molecule drug developed by RenJi Hospital.
Who makes hepatic artery infusion chemotherapy?
hepatic artery infusion chemotherapy is developed by RenJi Hospital (see full RenJi Hospital pipeline at /company/renji-hospital).
Is hepatic artery infusion chemotherapy also known as anything else?
hepatic artery infusion chemotherapy is also known as HAIC.
What development phase is hepatic artery infusion chemotherapy in?
hepatic artery infusion chemotherapy is in Phase 1.
Related
- Manufacturer: RenJi Hospital — full pipeline
- Also known as: HAIC
- Compare: hepatic artery infusion chemotherapy vs similar drugs
- Pricing: hepatic artery infusion chemotherapy cost, discount & access